Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 642-644

  Ortigas, Melina C ^a   Bourgeois, James A ^b   Schneider, Andrea ^a   Olichney, John ^c   Nguyen, Danh V ^d   Cogswell, Jennifer B ^a   Hall, Deborah A ^e   Hagerman, Randi J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMANTINE; VENLAFAXINE;

AGED; ATAXIA; CASE REPORT; CLINICAL FEATURE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; DRUG DOSE TITRATION; DRUG EFFICACY; DYSPHORIA; FEMALE; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; FRAGILE X SYNDROME; HUMAN; IMAGE ANALYSIS; IRRITABILITY; LETTER; NEUROIMAGING; PRIORITY JOURNAL; SENSORY NEUROPATHY; SYMPTOM; TREATMENT OUTCOME; TREMOR;

AGED; ATAXIA; CYCLOHEXANOLS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MEMANTINE; TREMOR;

EID: 77957275382     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181f1d10a     Document Type: Letter

References (19)

1. Maddalena A, Richards CS, McGinniss MJ, et al. Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee. Genet Med. 2001;3: 200-205.
2. Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet. 2004;74: 805-816.
3. Arocena DG, Iwahashi CK, Won N, et al. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neuronal cells. Hum Mol Genet. 2005;14: 3661-3671. (Pubitemid 41754666)
4. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet. 2003;72: 869-878. (Pubitemid 36403306)
5. Grigsby J, Brega AG, Jacquemont S, et al. Impairment in the cognitive functioning of men with fragile XYassociated tremor/ataxia syndrome (FXTAS). J Neurol Sci. 2006; 248: 227-233. (Pubitemid 44647291)
6. Hagerman PJ. The fragile X prevalence paradox. J Med Genet. 2008;45: 498-499.
7. Coffey SM, Cook K, Tartaglia N, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008;146A: 1009-1016.
8. Hall DA, Berry-Kravis E, Hagerman RJ, et al. Symptomatic treatment in the fragile XYassociated tremor/ataxia syndrome. Mov Disord. 2006;21: 1741-1744. (Pubitemid 44742210)
9. Hagerman RJ, Hall DA, Coffey S, et al. Treatment of fragile XYassociated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging. 2008;3: 251-262. (Pubitemid 352037865)
10. Jain KK. Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs. 2000;9: 1397-1406.
11. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997; 48(suppl 6): S10-S16.
12. Aguilar D, Sigford KE, Soontarapornchai K, et al. A quantitative assessment of tremor and ataxia in FMR1 premutation carriers using CATSYS. Am J Med Genet Part A. 2008;146A: 629-635.
13. Allen EG, Juncos J, Letz R, et al. Detection of early FXTAS motor symptoms using the CATSYS computerized neuromotor test battery. J Med Genet. 2008;45: 290-297. (Pubitemid 351685147)
14. Despres C, Lamoureux D, Beuter A. Standardization of a neuromotor test battery: the CATSYS system. Neurotoxicology. 2000;21: 725-735.
15. Grigsby J, Kaye K, Shetterly SM, et al. Prevalence of disorders of executive cognitive functioning among the elderly: findings from the San Luis Valley Health and Aging Study. Neuroepidemiology. 2002;21: 213-220. (Pubitemid 35002302)
16. Olichney JM, Van Petten C, Paller K, et al. Word repetition in amnesia: electrophysiological measures of impaired and spared memory. Brain. 2000;123: 1948-1963. (Pubitemid 30664297)
17. Adams PE, Adams JS, Nguyen DV, et al. Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B: 775-785.
18. Grunwald T, Heinz B, Lehnertz K, et al. Evidence relating human verbal memory to hippocampal N-methyl-D-aspartate receptors. PNAS. 1999;96: 12085-12089. (Pubitemid 29502862)
19. Erickson CA, Mullett JE, McDougle CJ. Open-label memantine in fragile X syndrome. J Autism Dev Disord. 2009;39: 1629-1635.